Earnings results for Arcturus Therapeutics (NASDAQ:ARCT)
Arcturus Therapeutics Holdings Inc. is expected* to report earnings on 11/09/2020 after market close. The report will be for the fiscal Quarter ending Sep 2020. According to Zacks Investment Research, based on 7 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.47. The reported EPS for the same quarter last year was $-0.56.
Arcturus Therapeutics last issued its quarterly earnings results on August 10th, 2020. The biotechnology company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.53) by $0.02. The firm had revenue of $2.32 million for the quarter, compared to the consensus estimate of $5.08 million. Arcturus Therapeutics has generated ($2.15) earnings per share over the last year. Arcturus Therapeutics has confirmed that its next quarterly earnings report will be published on Monday, November 9th, 2020. Arcturus Therapeutics will be holding an earnings conference call on Monday, November 9th. Interested parties can register for or listen to the call using this link.
Analyst Opinion on Arcturus Therapeutics (NASDAQ:ARCT)
11 Wall Street analysts have issued ratings and price targets for Arcturus Therapeutics in the last 12 months. Their average twelve-month price target is $57.64, predicting that the stock has a possible downside of 9.03%. The high price target for ARCT is $82.00 and the low price target for ARCT is $19.00. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Arcturus Therapeutics has received a consensus rating of Buy. The company’s average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings. According to analysts’ consensus price target of $57.64, Arcturus Therapeutics has a forecasted downside of 9.0% from its current price of $63.36. Arcturus Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Dividend Strength: Arcturus Therapeutics (NASDAQ:ARCT)
Arcturus Therapeutics does not currently pay a dividend. Arcturus Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: Arcturus Therapeutics (NASDAQ:ARCT)
In the past three months, Arcturus Therapeutics insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,432,700.00 in company stock. Only 12.60% of the stock of Arcturus Therapeutics is held by insiders. 53.12% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Arcturus Therapeutics (NASDAQ:ARCT
Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($2.13) to $1.01 per share. The P/E ratio of Arcturus Therapeutics is -24.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Arcturus Therapeutics is -24.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Arcturus Therapeutics has a P/B Ratio of 37.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here